![Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials - Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials -](https://www.thelancet.com/cms/asset/9dffa94a-4098-4902-bf61-ec9a648d6467/gr1.jpg)
Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials -
![Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines | Pharmacological Reviews Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines | Pharmacological Reviews](https://pharmrev.aspetjournals.org/content/pharmrev/74/1/313/F3.large.jpg)
Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines | Pharmacological Reviews
![COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes | Clinical Microbiology Reviews COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes | Clinical Microbiology Reviews](https://journals.asm.org/cms/asset/f8055cec-8574-4e33-a738-0492d6803dea/cmr.2022.35.issue-3.cover.gif)
COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes | Clinical Microbiology Reviews
![Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Oncology Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/90ff069c-1076-4be9-922e-3f762a514f3b/gr1.gif)
Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Oncology
![The global burden of cancer attributable to risk factors, 2010–19: a systematic analysis for the Global Burden of Disease Study 2019 - The Lancet The global burden of cancer attributable to risk factors, 2010–19: a systematic analysis for the Global Burden of Disease Study 2019 - The Lancet](https://www.thelancet.com/cms/attachment/c652217f-870a-4a98-976d-c433af9ee115/gr1.jpg)
The global burden of cancer attributable to risk factors, 2010–19: a systematic analysis for the Global Burden of Disease Study 2019 - The Lancet
![Evidence-based interventions for improvement of maternal and child nutrition: what can be done and at what cost? - The Lancet Evidence-based interventions for improvement of maternal and child nutrition: what can be done and at what cost? - The Lancet](https://www.thelancet.com/cms/asset/125e5fe1-01ef-4060-a913-b6bd2f9c7f28/gr1.jpg)
Evidence-based interventions for improvement of maternal and child nutrition: what can be done and at what cost? - The Lancet
![Amazon.com : LORENA-PELON PELON PELO RICO Tamarind Jelly Candy, Bulk, 1.06 oz Bottles (36 Count) : Grocery & Gourmet Food Amazon.com : LORENA-PELON PELON PELO RICO Tamarind Jelly Candy, Bulk, 1.06 oz Bottles (36 Count) : Grocery & Gourmet Food](https://m.media-amazon.com/images/I/610vTbOweZL.jpg)
Amazon.com : LORENA-PELON PELON PELO RICO Tamarind Jelly Candy, Bulk, 1.06 oz Bottles (36 Count) : Grocery & Gourmet Food
![Cancers | Free Full-Text | HPV16 Load Is a Potential Biomarker to Predict Risk of High-Grade Cervical Lesions in High-Risk HPV-Infected Women: A Large Longitudinal French Hospital-Based Cohort Study Cancers | Free Full-Text | HPV16 Load Is a Potential Biomarker to Predict Risk of High-Grade Cervical Lesions in High-Risk HPV-Infected Women: A Large Longitudinal French Hospital-Based Cohort Study](https://pub.mdpi-res.com/cancers/cancers-13-04149/article_deploy/html/images/cancers-13-04149-g001.png?1629286783)
Cancers | Free Full-Text | HPV16 Load Is a Potential Biomarker to Predict Risk of High-Grade Cervical Lesions in High-Risk HPV-Infected Women: A Large Longitudinal French Hospital-Based Cohort Study
![Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial - The Lancet Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial - The Lancet](https://www.thelancet.com/cms/attachment/2092216225/2076440337/gr1.gif)